Equioxx 20 mg/ml solution for injection for horses
Contra-indications, warnings, etc
Do not use in animals suffering from gastrointestinal disorders and haemorrhage, impaired hepatic, cardiac or renal function and bleeding disorders. Do not use in breeding, pregnant or lactating animals. Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs). Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not use in animals less than 10 weeks of age. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there may be potential risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic drugs should be avoided. Do not exceed the recommended treatment dose or duration of treatment. Mild reactions at the injection site characterised by swelling and associated with perivascular inflammation have been reported in clinical studies following administration of the product at the recommended dose. There is potential for the injection site reaction to be associated with pain. Lesions (erosion/ulceration) of the oral mucosa and of the skin around the mouth may occasionally be observed in treated animals. Typically, these lesions are mild and resolve without treatment, but oral lesions may be associated with salivation and labial and tongue oedema. The safety of the product for use in breeding, pregnant or lactating horses has not been evaluated. However, studies with laboratory animals have shown embryo-foetotoxicity, malformations, delayed parturition and decreased pup survival. Therefore, do not use in breeding, pregnant or lactating animals. Other NSAIDs, diuretic and substances with high protein binding may compete for binding and lead to toxic effects. Do not use concomitantly with corticosteroids or other NSAIDs. Pre-treatment with other anti-inflammatory substances may result in additional or increased adverse effects and a treatment-free period with such products should therefore be observed. The treatment-free period should take into account the pharmacological properties of the products used previously. Concurrent administration of potentially nephrotoxic drugs should be avoided as there might be an increased risk of renal toxicity. Concomitant treatment with molecules displaying action on renal flow (e.g. diuretics) should be subject to clinical monitoring.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. Avoid contact with eyes and skin. If this occurs, rinse affected area immediately with water. Wash hands after use of the product. Like other medicinal products that inhibit COX-2, pregnant women or women attempting to conceive should avoid contact with or wear disposable gloves when administering the product.
Meat and offal: 26 days. Do not use in mares producing milk for human consumption.